Axa’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Axa’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,950	Closed	-$112K	–	1420
2018 Q4	$112K	Sell	4,950 -5,867	-54%	-$229K	﹤0.01%	1269
2018 Q3	$597K	Hold	10,817	–	–	﹤0.01%	1120
2018 Q2	$772K	Hold	10,817	–	–	﹤0.01%	1061
2018 Q1	$664K	Hold	10,817	–	–	﹤0.01%	1097
2017 Q4	$1.36M	Buy	10,817 +720	+7%	+$92.2K	0.01%	936
2017 Q3	$1.38M	Buy	10,097 +9,172	+992%	+$1.23M	0.01%	898
2017 Q2	$132K	Buy	+925	New	+$143K	﹤0.01%	1220
2015 Q3	–	Sell	-9,926	Closed	-$9.42M	–	1536
2015 Q2	$9.42M	Hold	9,926	–	–	0.04%	438
2015 Q1	$7.27M	Buy	9,926 +3,566	+56%	+$2.68M	0.03%	476
2014 Q4	$5.05M	Buy	6,360 +2,356	+59%	+$1.27M	0.02%	555
2014 Q3	$1.6M	Buy	+4,004	New	+$1.07M	0.01%	804

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa's TTPH Position: Q1 2019 in Review

Axa sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2019, closing a stake of 4,950 shares — an estimated $112K sold.

Axa first reported a position in TTPH in Q3 2014 and held it in 11 quarters. The position peaked at $9.42M in Q2 2015. 78 funds tracked by Wall St. Rank hold TTPH as of Q1 2019.

Axa reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Axa sold 4,950 Tetraphase Pharmaceuticals, Inc. shares in Q1 2019, an estimated $112K.
Axa first reported a position in Tetraphase Pharmaceuticals, Inc. in Q3 2014 and held it in 11 quarters.
Axa's Tetraphase Pharmaceuticals, Inc. position peaked at $9.42M in Q2 2015.
78 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2019.

Based on Axa's 13F filing for Q1 2019, filed 14 May 2019.